New York and Mainz, Germany, January 15, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) developed a plan that will allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses in the second quarter.
New York, NY, January 15, 2021 – Pfizer Inc. (NYSE: PFE) – Today President-elect Biden released a COVID-19 vaccination plan that our scientists reviewed and believe will accelerate our ability to beat back the pandemic and save American lives. This comprehensive federal plan utilizes as many doses as possible, opens up eligibility to a broader set of Americans, and ensures equity by focusing on the hardest hit communities.
New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, to neutralize the SARS-CoV-2 U.K.
The Access to Medicine Foundation has ranked Pfizer among the top 5 pharmaceuticals in the 2021 Access to Medicine Index (ATMI). Pfizer moved up in the index from 11th to 4th place out of the top 20 pharmaceutical companies globally, representing the greatest increase in the ranking among the companies since the last report in 2018.
New York, NY and Mainz, Germany, January 29, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that data from an in vitro study on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize a pseudovirus bearing the SARS-CoV-2 U.K.
New York, NY and Mainz, Germany, February 1, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models from Pfizer and BioNTech’s mRNA-based vaccine candidates, BNT162b1 and BNT162b2, for the prevention of COVID-19 were published in the journal Nature.
New York, NY and Mainz, Germany, February 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from individuals vaccinated with the Pfizer- BioNTech COVID-19 vaccine neutralize SARS-CoV-2 with key mutations present in the United Kingdom (U.K.) and South African variants.
New York, NY and Mainz, Germany, February 17, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to neutralize SARS-CoV-2 with the South African variant spike protein.
New York, NY, February 19, 2021 — Today President Biden visited Pfizer’s Kalamazoo, MI facility, the largest manufacturing site in Pfizer’s network and the largest employer in the city of Kalamazoo. Established in 1948, Pfizer’s Kalamazoo site is one of three manufacturing plants in the U.S. that is currently engaged in the manufacture of the Pfizer-BioNTech COVID-19 Vaccine. Pfizer’s Kalamazoo facility is responsible for the formulation of the vaccine, and fill and finish activities.
New York, N.Y., February 25, 2021 – Pfizer Inc. (NYSE:PFE) stated today that, for the second year in a row, a recognized compensation expert confirmed equitable pay practices for employees at Pfizer.
The study assessed pay for gender worldwide and for minorities in the U.S. based on compensation data including base pay, merit increases and bonuses. The study measured the difference between similar groups of employees when adjusting for factors such as role, grade, job level, and location.